Etilevodopa: Difference between revisions

{{Short description|Chemical compound}}

{{Drugbox

| Watchedfields = changed

| verifiedrevid = 443949574

| IUPAC_name = ethyl (2''S'')-2-amino-3-(3,4-dihydroxyphenyl)propanoate

| image = Etilevodopa.svg

| width = 240

| image2 = Etilevodopa 3D ball.png

| alt2 = Ball-and-stick model of the etilevodopa molecule

<!--Clinical data-->

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

<!--Pharmacokinetic data-->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

<!--Identifiers-->

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 37178-37-3

| ATC_prefix = N04

| ATC_suffix = BA06

| ATC_supplemental = (combination with [[decarboxylase inhibitor]])

| PubChem = 170345

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 895X917GYE

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D04097

<!--Chemical data-->

| C=11 | H=15 | N=1 | O=4

'''Etilevodopa''' ('''TV-1203''') is a [[dopaminergic]] agent which was developed as a treatment for [[Parkinson's disease]].<ref>{{cite journal | vauthors = Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E | title = Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study | journal = Clinical Neuropharmacology | volume = 26 | issue = 6 | pages = 322–6 | date = November–December 2003 | pmid = 14646613 | doi = 10.1097/00002826-200311000-00012 | s2cid = 23992241 }}</ref> It is the [[ethyl group|ethyl]] [[ester]] of [[levodopa]]. It was never marketed.

{{Reflist}}

[[Category:Neurotransmitter precursors]]

[[Category:Propionate esters]]

[[Category:Ethyl esters]]

[[Category:Abandoned drugs]]